RedPath Integrated Pathology Inc, a molecular diagnostics company dedicated to the effective diagnosis and treatment of cancer, announces that its Board of Directors has named Mark D. Myslinski to serve as RedPath’s President and Chief Executive Officer effective immediately.
Myslinski brings nearly thirty years of life sciences and diagnostics industry experience to RedPath, including key sales and operating roles in both Fortune 100 and venture-backed start-up organizations. Myslinski has been a Johnson & Johnson executive since 2002 where his responsibilities have included building a new, world-wide Evidence Based Medicine function for the Ortho-Clinical Diagnostics unit. Myslinski was also General Manager of Johnson & Johnson’s Veridex, LLC, a division focused on molecular diagnostics that achieved triple-digit sales growth under Myslinski’s tenure.
Previously, Myslinski held executive roles in venture-backed start-ups, Interscope Technologies and Precision Therapeutics, both focused on the field of pathology with an emphasis on cancer. Myslinski also accumulated over twenty years of sales and marketing experience prior to these roles, including over eight years with Baxter/American Hospital Supply Corporation.
Brian G. Murphy, RedPath’s non-executive Chairman and General Partner of NewSpring Health Capital, commented that the RedPath Board was attracted to Myslinski’s sales and marketing track record, in particular, Myslinski’s extensive commercial experience in the molecular diagnostic space.
“Mark is a seasoned executive with considerable experience in developing novel diagnostics for broad market adoption,” said Murphy. “As we prepare to further penetrate the market for RedPath’s PathFinderTG®, a diagnostic platform that resolves diagnostic dilemmas, to a broader audience of clinicians, pathologists, patients and payor organizations, Mark’s track record in these areas clearly made him our top choice.”
Mark Myslinski, RedPath’s new Chief Executive Officer, added, “I look forward to building a world-class company squarely in the fight against cancer utilizing molecular tools to solve unmet needs. More than ever, the healthcare industry needs more accurate and objective diagnostic tools for the effective treatment of cancer and I believe that RedPath has tremendous potential to lead this challenge.”
Myslinski replaces founding CEO, Mary Del Brady, who remains an active investor in RedPath.
Source: RedPath Integrated Pathology